Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions
This disclosure provides compositions and related methods providing targeted cell-specific inhibition of Notch receptor signaling. The disclosure provides a bi-specific molecule with separate domains that target the intended cell-type and the Notch receptor on that cell-type. The disclosure also provides for nucleic acids, vectors, and cells allowing for the expression of the bi-specific fusion molecules. The disclosure also provides related methods of making and using the bi-specific fusion molecule to inhibit Notch signaling in target cells of interest, including for the treatment of diseases characterized by a dysregulation of Notch signaling.
1. A bi-specific molecule, comprising:
a cell-targeting domain that specifically binds to CD33; and
a Notch-binding domain comprising the extracellular domain of a Notch receptor ligand that binds to a Notch receptor on a cell-type of interest.
2. The molecule of claim 1 , wherein the Notch-binding domain comprises the extracellular domain of a mammalian Notch receptor ligand.
3. The molecule of claim 2 , wherein the mammalian Notch receptor ligand is a ligand to a mammalian Notch1, Notch2, Notch3, or Notch4 receptor.
4. The molecule of claim 2 , wherein the mammalian Notch receptor ligand is a Delta protein or Jagged protein.
5. The molecule of claim 4 , wherein the Delta protein is Delta Like Ligand 1 (DLL1), DLL3, or DLL4, or wherein the Jagged protein is Jagged 1 or Jagged 2.
6. The molecule of claim 2 , wherein the mammalian Notch receptor ligand is Dlk1, Dlk2, DNER, EGFL 7, or F3/contactin.
7. The molecule of claim 2 , wherein the extracellular domain of the Notch receptor ligand contains one or more mutations from a wild-type extracellular domain of a Notch receptor ligand resulting in enhanced affinity or specificity of the extracellular domain of the Notch receptor ligand to the Notch receptor as compared to the wild-type extracellular domain, and wherein:
the Notch-binding domain comprises an extracellular fragment of Delta Like Ligand 4 (DLL4) that comprises an N-terminus Notch ligand (MNNL) domain, Delta-Serrate-Lag2 (DSL) domain, and epidermal growth factor (EGF) repeats 1-8 and the one or more mutations from wild-type are selected from G28S, M/V43I, P52S, S96I, F107L, N118I, I143F/T, Q146K, S183N, H194Y, L206P, K215E, L223R, and M257K with respect to the amino acid sequence set forth in SEQ ID NO: 1 or a homologous sequence thereto; or
the Notch-binding domain comprises an extracellular fragment of Jagged 1 that comprises an N-terminus Notch ligand (MNNL) domain, Delta-Serrate-Lag2 (DSL) domain, and epidermal growth factor (EGF) repeats 1-8 and the one or more mutations from wild-type are selected from P100H and Q183P with respect to the amino acid sequence set forth in SEQ ID NO: 4 or a homologous sequence thereto.
8. The molecule of claim 1 , wherein the cell-targeting domain comprises an antibody, an antibody fragment, an antibody derivative, a DARpin, an aptamer, or a functional domain thereof.
9. The molecule of claim 8 , wherein the antibody fragment or antibody derivative is a single-chain antibody, a bispecific antibody, an Fab fragment, an F(ab) 2 fragment, a V H H fragment, a V NAR fragment, or a nanobody.
10. The molecule of claim 1 , wherein the cell-targeting domain specifically binds to CD33 with an affinity characterized by a dissociation constant (K d ) of 50 nM or less.
11. The molecule of claim 1 , wherein the cell-type of interest is a cancer cell or cancer progenitor/stem cell.
12. The molecule of claim 11 , wherein the cancer cell is a leukemic cell or a progenitor thereof.
13. The molecule of claim 1 , wherein the cell-targeting domain and the Notch-binding domain are joined by at least an intervening flexible linker domain.
14. The molecule of claim 1 , wherein the molecule is a fusion polypeptide and each of the cell-targeting domain and Notch-binding domain are polypeptides that do not naturally occur together.
15. A nucleic acid encoding the fusion polypeptide of claim 14 .
16. A vector comprising the nucleic acid of claim 15 .
17. A cultured cell comprising the vector of claim 16 .
18. A pharmaceutical composition comprising the molecule of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
19. The molecule of claim 1 , wherein the extracellular domain of the Notch receptor ligand binds to the Notch receptor with an affinity characterized by a dissociation constant (K d ) of about 100 nM to about 0.1 nM.